Evidence map›Paper›PMID 36678561›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Formation and Characterisation of Posaconazole Hydrate Form.

Michail Lykouras, Malvina Orkoula, Christos Kontoyannis

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michail LykourasDepartment of Pharmacy, University of Patras, GR-26504 Rio, Achaias, Greece.ORCID 0000-0001-7864-0911
Malvina OrkoulaDepartment of Pharmacy, University of Patras, GR-26504 Rio, Achaias, Greece.ORCID 0000-0003-3023-2075
Christos KontoyannisDepartment of Pharmacy, University of Patras, GR-26504 Rio, Achaias, Greece.ORCID 0000-0003-0452-1957

Funding

Hellenic Foundation for Research and Innovation (HFRI) 1298
6 · The paper itself

Abstract

Posaconazole is an API added as Form I for the production of oral suspensions, but it is found as Form-S in the final formulation. In this study, it was found that this polymorphic conversion, which may affect the bioavailability, is due to an interaction with water. However, the relatively poor wettability of posaconazole Form I renders the complete wetting of its particles and production of pure Form-S challenging. Consequently, for its isolation, Form I should be dispersed in water followed by application of sonication for at least 10 min. Pure posaconazole Form-S was characterised using X-ray powder diffraction (XRPD), Raman spectroscopy, attenuated total reflection (ATR) spectroscopy, thermogravimetric analysis (TGA) and optical microscopy. From these techniques, posaconazole Form-S was characterised as a hydrate form, which includes three molecules of water per API molecule.

Indexed as

attenuated total reflection (ATR)Form-Shydrateoptical microscopyoral suspensionpolymorphismposaconazoleRaman spectroscopythermal analysisX-ray powder diffraction (XRPD)

Identifiers

PMID36678561
PMCPMC9862180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.